<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase II:   Novel Method for Class Switching IgM Secretors to IgG</AwardTitle>
<AwardEffectiveDate>01/01/2003</AwardEffectiveDate>
<AwardExpirationDate>12/31/2005</AwardExpirationDate>
<AwardTotalIntnAmount>500000.00</AwardTotalIntnAmount>
<AwardAmount>641950</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>F.C. Thomas Allnutt</SignBlockName>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase II project proposes to develop a rapid IgSwitch  Assay for inducing and isolating IgG class switch variants from IgM hybridomas using in-vitro culture conditions, microencapsulation technology and fluorescence activated cell sorting. The IgSwitch  Assay is expected to be a significant improvement over conventional methods used to isolate class switch variants, and will be useful in cell line development and monoclonal antibody production. Prior Phase I research has already demonstrated the feasibility of the proposed method using a model IgM hybridoma. This Phase II project will develop in-vitro culture conditions that promote switching to different IgG subclasses. The Phase II research will also validate reagents for a family of isotype specific IgSwitch  Assays. &lt;br/&gt;&lt;br/&gt;The commercial application of this project will be in the area of monoclonal antibodies. Use of the targeted IgSwitch Assay in monoclonal antibody production will help to generate new IgG specific antibodies from a largely untapped source of IgM hybridomas, for potential use as research, therapeutic, diagnostic, and imaging reagents.&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt; &lt;br/&gt;&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>12/20/2002</MinAmdLetterDate>
<MaxAmdLetterDate>06/08/2005</MaxAmdLetterDate>
<ARRAAmount/>
<AwardID>0238667</AwardID>
<Investigator>
<FirstName>Yevgenya</FirstName>
<LastName>Akselband</LastName>
<EmailAddress>yaks@onecell.com</EmailAddress>
<StartDate>12/20/2002</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>ONE CELL SYSTEMS, INC</Name>
<CityName>CAMBRIDGE</CityName>
<ZipCode>021399129</ZipCode>
<PhoneNumber>6178682399</PhoneNumber>
<StreetAddress>100 INMAN ST STE 200</StreetAddress>
<CountryName>United States</CountryName>
<StateName>Massachusetts</StateName>
<StateCode>MA</StateCode>
</Institution>
<FoaInformation>
<Code>0308000</Code>
<Name>Industrial Technology</Name>
</FoaInformation>
<FoaInformation>
<Code>0522100</Code>
<Name>High Technology Materials</Name>
</FoaInformation>
<ProgramElement>
<Code>5373</Code>
<Text>SBIR Phase II</Text>
</ProgramElement>
<ProgramReference>
<Code>1517</Code>
<Text>ELECT, PHOTONICS, &amp; DEVICE TEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9102</Code>
<Text>WOMEN, MINORITY, DISABLED, NEC</Text>
</ProgramReference>
<ProgramReference>
<Code>9148</Code>
<Text>TOOLS &amp; TECHNOL FOR MANUFACTURING DESIGN</Text>
</ProgramReference>
<ProgramReference>
<Code>9178</Code>
<Text>UNDERGRADUATE EDUCATION</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>9231</Code>
<Text>SUPPL FOR UNDERGRAD RES ASSIST</Text>
</ProgramReference>
<ProgramReference>
<Code>9251</Code>
<Text>REU SUPP-Res Exp for Ugrd Supp</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
</Award>
</rootTag>
